HUP0301400A2 - Gyógyszerösszetétel és adagolási forma az alendronát és/vagy más biszfoszfonátoknak a gyomorban történż késleltetett felszabadulására - Google Patents

Gyógyszerösszetétel és adagolási forma az alendronát és/vagy más biszfoszfonátoknak a gyomorban történż késleltetett felszabadulására

Info

Publication number
HUP0301400A2
HUP0301400A2 HU0301400A HUP0301400A HUP0301400A2 HU P0301400 A2 HUP0301400 A2 HU P0301400A2 HU 0301400 A HU0301400 A HU 0301400A HU P0301400 A HUP0301400 A HU P0301400A HU P0301400 A2 HUP0301400 A2 HU P0301400A2
Authority
HU
Hungary
Prior art keywords
alendronate
dosage form
phosphpnates
bis
composition
Prior art date
Application number
HU0301400A
Other languages
English (en)
Inventor
Mazal Dahan
Moshe Flashner-Barak
Yitzhak Lerner
Vered Rosenberger
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HUP0301400A2 publication Critical patent/HUP0301400A2/hu
Publication of HUP0301400A3 publication Critical patent/HUP0301400A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya orális gyógyászati készítmény, amely a gyomornedvhatására duzzad, a gyomorban hosszabb ideig tartózkodik és nemhidratált hidrogélt, fokozott szétesést segítő anyagot és csersavattartalmaz. A találmány további tárgya dózisforma, amely a hatóanyag(biszfoszfonát, pl. alendronát ) hosszabb időn keresztül történőleadására képes. Ó
HU0301400A 2000-06-23 2001-06-22 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphpnates HUP0301400A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21383200P 2000-06-23 2000-06-23
US26043801P 2001-01-09 2001-01-09
US09/770,898 US6476006B2 (en) 2000-06-23 2001-01-26 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
PCT/US2001/020130 WO2002000204A1 (en) 2000-06-23 2001-06-22 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates

Publications (2)

Publication Number Publication Date
HUP0301400A2 true HUP0301400A2 (hu) 2003-09-29
HUP0301400A3 HUP0301400A3 (en) 2005-02-28

Family

ID=27395916

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301400A HUP0301400A3 (en) 2000-06-23 2001-06-22 Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphpnates

Country Status (12)

Country Link
US (2) US6476006B2 (hu)
EP (1) EP1296657A1 (hu)
JP (1) JP2004501186A (hu)
KR (1) KR20030023879A (hu)
AU (2) AU6871901A (hu)
CA (1) CA2412024A1 (hu)
CZ (1) CZ2003211A3 (hu)
EA (1) EA007247B1 (hu)
HU (1) HUP0301400A3 (hu)
IL (1) IL153443A0 (hu)
MX (1) MXPA02012792A (hu)
WO (1) WO2002000204A1 (hu)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608640B2 (en) * 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
EP1416919A1 (en) * 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
NZ534104A (en) * 2001-12-24 2007-03-30 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
KR20120065435A (ko) 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
US20050026871A1 (en) * 2002-07-17 2005-02-03 Moshe Flashner-Barak Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
DE20321698U1 (de) 2002-12-16 2008-12-24 Teva Pharmaceutical Industries Ltd. Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats
BR0309691A (pt) 2002-12-20 2005-08-02 Hoffmann La Roche Formulação de ibandronato em alta dose
US6846497B2 (en) * 2003-01-30 2005-01-25 National Starch And Chemical Investment Holding Corporation Rapidly expanding starches with altered crystalline structure
SI21403A (sl) * 2003-02-27 2004-08-31 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z alendronsko kislino, njenimi solmi ali estri ter postopek za njeno pripravo
ES2278314T3 (es) * 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
ATE512659T1 (de) 2003-04-24 2011-07-15 Jagotec Ag Tablette mit verzögerter wirkstofffreigabe und bestimmter formgeometrie
US20060128657A1 (en) * 2003-08-04 2006-06-15 Jallal Messadek Selected betaines and their uses
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
US6783772B1 (en) * 2003-12-12 2004-08-31 Sanjeev Khandelwal Pharmaceutical preparations containing alendronate sodium
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
BRPI0610249A2 (pt) * 2005-04-27 2010-06-08 Jallal Messadek associação ou combinação farmacêutica, composição farmacêutica, processo de co-cristalização e o uso de insulina ou análogo de insulina
US7765785B2 (en) * 2005-08-29 2010-08-03 Kashmerick Gerald E Combustion engine
EP1973530A2 (en) * 2005-12-30 2008-10-01 Advancis Pharmaceutical Corporation Gastric release pulse system for drug delivery
WO2008079440A2 (en) 2006-07-10 2008-07-03 Medipacs, Inc. Super elastic epoxy hydrogel
DK2049123T4 (en) 2006-08-03 2016-11-28 Horizon Pharma Ag LATE discharge-glucocorticoid treatment of rheumatoid ILLNESS
WO2008020305A2 (en) * 2006-08-17 2008-02-21 Aurobindo Pharma Limited Solid dosage forms of bisphosphonic acids
EP1935411A1 (en) * 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Slow release excipient and its use
ATE471714T1 (de) * 2006-12-15 2010-07-15 Campina Nederland Holding Bv Hilfsstoff mit verzögerter freisetzung und seine verwendung
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
MX2010001629A (es) * 2007-08-10 2010-08-09 Alessandro Sannino Hidrogeles de polimero y metodos de preparacion de los mismos.
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
EP2227635A2 (en) 2007-12-03 2010-09-15 Medipacs, Inc. Fluid metering device
US9457048B2 (en) 2008-02-05 2016-10-04 Wellosophy Corporation Absorbent ingestible agents and associated methods of manufacture and use
EP2210585A1 (en) 2009-01-16 2010-07-28 Exelgyn SPRM pharmaceutical compositions methods of treatment using them
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
ES2650665T3 (es) * 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US9238102B2 (en) 2009-09-10 2016-01-19 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
FR2952937B1 (fr) * 2009-11-20 2013-02-08 Chaire Europeenne De Chimie Now Pour Un Developpement Durable Nouvelles resines de type phenoplastes obtenues a partir de composes phenoliques et de durcisseurs macromoleculaire portant des fonctions aldehydes
US20110172637A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172639A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172609A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
US20110172645A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
WO2012061556A1 (en) 2010-11-03 2012-05-10 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
KR101324425B1 (ko) * 2011-07-22 2013-11-01 동아에스티 주식회사 증가된 비스포스포네이트의 생체이용률을 가지는 경구투여 약제
CN104302689A (zh) 2012-03-14 2015-01-21 麦德医像公司 含有过量活性分子的智能聚合物材料
EP3091962B1 (en) * 2013-12-05 2022-06-08 Epitomee Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
JP6823539B2 (ja) * 2017-05-26 2021-02-03 株式会社ファンケル 胃内滞留性錠剤
CA3082184A1 (en) 2017-12-01 2019-06-06 Ultragenyx Pharmaceutical Inc. Creatine prodrugs, compositions and methods of use thereof
US11826473B2 (en) * 2018-01-11 2023-11-28 Sawai Pharmaceutical Co., Ltd. Orally disintegrating tablet coated with film
JP7044649B2 (ja) * 2018-06-28 2022-03-30 株式会社ファンケル 胃内浮遊錠剤

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3995058A (en) 1973-12-12 1976-11-30 Miles Laboratories, Inc. Treatment of ethanol withdrawal symptoms with levodopa
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4764380A (en) 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4758436A (en) 1985-05-29 1988-07-19 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4704285A (en) 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US4983398A (en) 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
JPH04346919A (ja) 1991-05-27 1992-12-02 Shin Etsu Chem Co Ltd 徐放性錠剤の製造方法
US5198229A (en) 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
TW257765B (hu) 1993-08-25 1995-09-21 Merck & Co Inc
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
JP3601102B2 (ja) 1995-03-15 2004-12-15 ブラザー工業株式会社 インクジェット式印刷記録装置と印字システム
EP0837863A4 (en) 1995-06-06 1999-06-16 Merck & Co Inc DISODIUM ALENDRONATE PREPARATIONS
US5840756A (en) 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
EP0761209A3 (en) 1995-09-01 1998-02-04 J.B. Chemicals & Pharmaceuticals Ltd. Controlled release formulations of ranitidine
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
CA2296654A1 (en) 1997-07-23 1999-02-04 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity
PT1003476E (pt) 1997-08-11 2005-05-31 Alza Corp Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
IN186245B (hu) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration

Also Published As

Publication number Publication date
US20030203878A1 (en) 2003-10-30
JP2004501186A (ja) 2004-01-15
CZ2003211A3 (en) 2004-03-17
WO2002000204A1 (en) 2002-01-03
EP1296657A1 (en) 2003-04-02
KR20030023879A (ko) 2003-03-20
EA200300045A1 (ru) 2003-08-28
US6476006B2 (en) 2002-11-05
EA007247B1 (ru) 2006-08-25
MXPA02012792A (es) 2004-07-30
IL153443A0 (en) 2003-07-06
AU2001268719B2 (en) 2006-04-27
AU6871901A (en) 2002-01-08
US20020015733A1 (en) 2002-02-07
CA2412024A1 (en) 2002-01-03
HUP0301400A3 (en) 2005-02-28

Similar Documents

Publication Publication Date Title
HUP0301400A2 (hu) Gyógyszerösszetétel és adagolási forma az alendronát és/vagy más biszfoszfonátoknak a gyomorban történż késleltetett felszabadulására
HUP0103883A2 (hu) Új, késleltetett felszabadulású, orális készítmények
MXPA02012793A (es) Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.
AP1748A (en) Chronotherapeutic dosage forms.
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
EP1566174A3 (en) Flash-melt oral dosage formulation
MXPA04007980A (es) Preparado farmaceutico de sabor enmascarado en forma de pelicula o de oblea.
WO2004112711A3 (en) Oral extended-release composition
BG108516A (en) Pharmaceutical formulation
TR200200562T2 (tr) Vücutta kontrollü şekilde salgılanabilen ve nahoş tadı önleyebilen ağızdan alınmaya mahsus farmasötik bileşimler
HUP0201877A2 (hu) Hal zselatint tartalmazó, gyorsan diszpergálódó dózis formák
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
MXPA05010196A (es) Nuevas formulaciones y su uso.
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
EP0966966A3 (en) Nefazodone dosage form
IL154731A0 (en) Ion-strength independent sustained release pharmaceutical formulation
HUP9801227A2 (hu) Monoamin-oxidáz B inhibitorokból álló gyógyászati készítmények és alkalmazásuk
HUP0401308A2 (hu) Folyékony polimer kompozíció szájüregi betegségek megelőzésére és kezelésére
HUP0402178A2 (hu) 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
WO2002067894A3 (en) Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
WO2005062722A3 (en) Fexofenadine containing pharmaceutical formulation